广东精诚粤衡律师事务所 关于 广东宝莱特医用科技股份有限公司 2021 年限制性股票激励计划 法律意见书 广东精诚粤衡律师事务所 广东省珠海市情侣中路 47 号怡景湾大酒店五层 电话：（0756）-8893339 传真：（0756）-8893336 作废部分已授予尚未归属的限制性股票的 广东精诚粤衡律师事务所 关于广东宝莱特医用科技股份有限公司 2021 年限制性股票激励计划作废部分已授予尚未归属的 2、本所律师同意将本法律意见书作为公司本次作废所必备的法定文件之一， 1 随同其他材料一同上报或者公开披露，并就本法律意见书内容的真实性、准确性 及完整性依法承担相应的法律责任。 3、本所律师同意公司及公司聘请的其他中介机构按照中国证监会的审核要 求部分或全部引用或引用本法律意见书的内容，但在引用时，不得因引用而导致 法律上的歧义或曲解。 4、本所经办律师已经审阅了出具本法律意见书所需的有关文件和资料，并 据此出具法律意见，但对于审计、财务等专业事项，本法律意见书只作引用而不 发表法律意见。本所经办律师在本法律意见书中对有关会计报表、数据、公式、 审计报告中某些数据和结论的引述，并不意味着对该等数据和相关结论的合 ...

宝莱特：独立董事 2023 年度述职报告（薛俊东） 各位董事、各位股东： 本人作为广东宝莱特医用科技股份有限公司（以下简称"公司"）的第八届 董事会独立董事，根据《公司法》《证券法》《上市公司治理准则》、中国证监 会《上市公司独立董事管理办法》等有关法律法规以及《公司章程》《独立董事 工作制度》等公司制度的规定，在 2023 年工作中，本人定期了解检查公司经营 情况，认真履行了独立董事的职责，恪尽职守，勤勉尽责。本人积极出席相关会 议，认真仔细审阅会议议案及相关材料，参与议题讨论并提出合理建议，对董事 会的相关事项发表独立意见，充分发挥独立董事作用，以维护公司和全体股东特 别是中小股东的合法权益。现将本人履行独立董事职责情况报告如下： 一、出席公司董事会和股东大会情况 公司 2023 年度共召开的 9 次董事会，2 次股东大会。在本人 2023 年度任期 内，参加了 9 次董事会，2 次股东大会。任职期间本人严格按照有关法律法规的 要求，勤勉履行独立董事的职责，对公司提交董事会审议的各项议案及相关事项 均进行了认真的审核及查验，对需表决的相关议案均投了赞成票，无反对票及弃 权票。本人认为，公司董事会会议的召集 ...

证券代码：300246 证券简称：宝莱特 公告编号：2024-031 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 关于续聘公司 2024 年度财务审计机构的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 广东宝莱特医用科技股份有限公司（以下简称"公司"）于 2024 年 4 月 24 日 召开第八届董事会第十四次会议，审议通过了《关于续聘公司 2024 年度财务审 计机构的议案》，公司拟续聘大华会计师事务所（特殊普通合伙）（以下简称"大 华会所"）为公司 2024 年度的审计机构，本事项需提交公司 2023 年度股东大会 审议，现将具体内容公告如下： 一、拟续聘会计师事务所基本情况 大华会计师事务所（特殊普通合伙）（以下简称"大华会所"）具备证券、期 货相关业务执业资格，具备多年为上市公司提供审计服务的经验与能力。在担任 公司2023年度审计机构期间，大华会所恪尽职守，遵循独立、客观、公正的审计 准则，公允合理地发表审计意见，较好地完成了公司2023年度财务报告审计的各 项工作，为保持审计工作连续性，公司董事会拟续聘大华会所为 ...

宝莱特：内部控制自我评价报告 广东宝莱特医用科技股份有限公司 内部控制自我评价报告 广东宝莱特医用科技股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称"企业内部控制规范体系"），结合广东宝莱特医用科技股份有限公 司（以下简称"公司"）内部控制制度和评价办法，在内部控制日常监督和专项监 督的基础上，我们对公司2023年12月31日（以下简称"内部控制评价报告基准日"） 的内部控制的有效性进行了自我评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经营层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存 在的固有局限性，故仅能为实现上述 ...

Revenue and Profit - Revenue for Q1 2024 was CNY 266.86 million, a decrease of 22.55% compared to CNY 344.57 million in the same period last year[5] - Net profit attributable to shareholders was CNY 3.63 million, down 86.65% from CNY 27.16 million year-on-year[5] - The company reported a significant decrease in operating profit, which fell by 85.47% to CNY 5.23 million from CNY 36.00 million year-on-year[9] - The total profit decreased by 84.11% to CNY 5.10 million compared to CNY 32.09 million in the same period last year[9] - Basic and diluted earnings per share were CNY 0.0137, a decline of 91.13% from CNY 0.1545 in the same period last year[5] - Net profit for Q1 2024 was ¥4,430,173.89, a decline of 84.4% from ¥28,305,836.21 in Q1 2023[22] - The company reported a total comprehensive income of ¥3,974,456.23 for Q1 2024, compared to ¥28,710,677.12 in Q1 2023[22] Cash Flow - The net cash flow from operating activities improved by 61.38%, reaching -CNY 24.71 million compared to -CNY 63.98 million in the previous year[5] - The net cash flow from operating activities decreased by 39,272,475.45, a reduction of 61.38% compared to the previous period, primarily due to decreased procurement payments[10] - The cash received from investment recoveries was 66,900,000.00, marking a 100.00% increase, attributed to the recovery of principal from financial products[10] - The cash flow from investment activities totaled 74,391,457.29, an increase of 247,871.52%, mainly due to the recovery of principal from financial products[10] - The net cash flow from financing activities increased by 54,307,615.87, a rise of 122.56%, primarily due to increased bank loan repayments[10] - The company reported a cash increase of CNY 86,453,209.03 in Q1 2024, compared to CNY 32,130,753.01 in Q1 2023, marking a significant rise of approximately 169.9%[25] Assets and Liabilities - Total assets increased by 1.61% to CNY 2.58 billion from CNY 2.53 billion at the end of the previous year[5] - The company reported a total asset of CNY 2,575,176,425.17 as of March 31, 2024, an increase from CNY 2,534,398,019.03 at the beginning of the period, reflecting a growth of approximately 1.6%[17] - The total liabilities amounted to CNY 1,189,312,347.03, up from CNY 1,145,452,995.95, indicating an increase of approximately 3.8%[19] - The company’s long-term borrowings increased by 63.96% to CNY 144.84 million, reflecting increased bank loans during the reporting period[9] - The company’s long-term borrowings increased to CNY 144,840,000.00 from CNY 88,340,000.00, showing a significant rise of approximately 63.8%[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,648[12] - The largest shareholder, Yan Jinyuan, holds 26.72% of the shares, totaling 70,705,185 shares, with 7,980,000 shares pledged[13] - The company has repurchased a total of 1,073,550 shares, accounting for 0.4058% of the total share capital, with a total expenditure of between CNY 20 million and CNY 30 million planned for the buyback[16] - The company plans to implement an employee stock ownership plan or equity incentive through the repurchased shares[16] Expenses - Sales expenses decreased by 30.38% to CNY 34.35 million, attributed to improved efficiency in the sales department[9] - Research and development expenses decreased to ¥18,430,075.31, down 25.7% from ¥24,786,031.00 in the previous year[21] Legal Matters - The company is actively monitoring a patent infringement lawsuit with Shenzhen Mindray Bio-Medical Electronics Co., Ltd., and will take necessary measures to protect its rights[15] Accounting Standards - The company did not undergo an audit for the Q1 2024 report[26] - The company has adopted new accounting standards starting from 2024, impacting the financial statements[26]

广东宝莱特医用科技股份有限公司 关于营业收入扣除事项的 专项核查意见 一、 关于营业收入扣除事项的专项核查意见 1-2 二、 营业收入扣除情况明细表 1-2 大华核字[2024]0011006720 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants（Special General Partnership） 广东宝莱特医用科技股份有限公司 关于营业收入扣除事项的 专项核查意见 （2023 年 1 月 1 日至 2023 年 12 月 31 日止） | | | 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层 [100039] 电话：86 (10) 5835 0011 传真：86 (10) 5835 0006 www.dahua-cpa.com 关于营业收入扣除事项的 我们接受委托，对广东宝莱特医用科技股份有限公司（以下简称 宝莱特公司）2023 年度财务报表进行审计，并出具了大华审字 [2024]0011004608 号审计报告。在此基础上我们检查了贵公司编制的 后附 2023 年度营 ...

Financial Performance - In 2023, the company recorded a significant decline in net profit attributable to shareholders, primarily due to impairment losses totaling RMB 116.58 million[4]. - The company's operating revenue for 2023 was CNY 1,194,001,129.61, representing a year-on-year increase of 0.87% compared to CNY 1,183,699,680.25 in 2022[24]. - The net profit attributable to shareholders for 2023 was a loss of CNY 65,185,130.69, a significant decline of 394.52% from a profit of CNY 21,997,981.33 in 2022[24]. - The net cash flow from operating activities decreased by 8.30% to CNY 129,047,347.24 in 2023, down from CNY 140,721,997.37 in 2022[24]. - The total equity attributable to shareholders decreased by 7.43% to CNY 1,310,894,066.37 at the end of 2023 from CNY 1,416,280,945.50 at the end of 2022[24]. - The company indicated uncertainty regarding its ability to continue as a going concern, as reflected in the audit report for the most recent year[25]. - The company will not distribute cash dividends, issue bonus shares, or increase capital from reserves[7]. - The company reported a significant increase in non-operating losses, with a total of CNY 16,318,188.91 in 2023 compared to CNY 28,653,932.63 in 2022[31]. Market Trends and Opportunities - The medical device industry remains prosperous, with no signs of overcapacity or continuous decline[4]. - The global medical device market size reached $552.8 billion in 2022, with a year-on-year growth of 5.9%[35]. - China's medical device market size exceeded ¥900 billion in 2022, projected to surpass ¥2.2 trillion by 2030, becoming the largest in the world[36]. - The blood purification industry is experiencing a clear growth trend, supported by government policies and increasing market demand for innovative products and technologies[44]. - The company plans to enhance operational management and leverage opportunities in domestic medical device replacement and hospital upgrades[6]. - The government has implemented policies to enhance the construction of medical resources, including the establishment of independent hemodialysis centers in major cities[41]. Research and Development - Research and development investment amounted to 93.35 million yuan, a year-on-year increase of 3%[58]. - The company and its subsidiaries held a total of 381 patents, with 83 new patents added during the reporting period[60]. - The company has established a comprehensive layout in the blood purification equipment and consumables sector, with nine consumable bases and three channel platforms[45]. - The company emphasizes R&D, maintaining a collaborative development process to ensure the conversion of technological innovations into marketable products[53]. - The company is committed to ongoing research and development of new medical technologies to meet market demands and improve healthcare outcomes[1]. Product Development and Innovation - The company aims to build a kidney medical ecosystem through a full industry chain, regional coverage, specialized operations, and lean management[45]. - The company is focused on expanding its product line in the blood purification sector, which is expected to enhance market competitiveness[96]. - The company has launched several new products, including the S200 enteral nutrition pump and various models of infusion and injection pumps[62]. - The company is exploring strategic acquisitions to enhance its product portfolio and expand its technological capabilities in the healthcare sector[61]. - The company aims to enhance its technological capabilities with the introduction of new software systems for its medical devices[62]. Corporate Governance and Management - The company has established a layered governance structure involving the shareholders' meeting, board of directors, supervisory board, and management[162]. - The company has implemented strict information disclosure practices, ensuring timely and accurate communication with investors[165]. - The board of directors consists of 9 members, including 3 independent directors, and has held 9 meetings during the reporting period[165]. - The company has established a performance evaluation and incentive system for its directors, supervisors, and senior management, ensuring that compensation is linked to actual performance[166]. - The company is committed to improving its corporate governance structure in compliance with relevant laws and regulations[162]. Strategic Outlook - Future outlook includes plans to expand market presence in Southeast Asia, targeting a 15% increase in market share by 2025[61]. - The company has set a revenue guidance of approximately $150 million for the next fiscal year, representing a 20% increase compared to the previous year[61]. - The company plans to adjust the internal investment structure for the marketing network and information technology construction projects[126]. - The company aims to enhance operational efficiency by optimizing organizational structure and improving internal control systems, with a focus on cost control and risk management[143]. - The company is actively pursuing market expansion strategies to increase its footprint in the medical technology industry[19][22].

债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 证券代码：300246 证券简称：宝莱特 公告编号：2024-039 关于会计政策变更的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 广东宝莱特医用科技股份有限公司（以下简称"公司"）根据中华人民共和国 财政部（以下简称"财政部"）颁布的《企业会计准则解释第 17 号》（财会〔2023〕 21 号）（以下简称"《准则解释第 17 号》"）的要求变更相应的会计政策。公司 本次会计政策变更事项属于根据法律法规或者国家统一的会计制度要求的会计 政策变更，不会对公司财务状况、经营成果和现金流量产生重大影响。根据《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有 关规定，该事项无需提交公司董事会、股东大会审议。相关会计政策变更的具体 情况如下： 一、本次会计政策变更的概述 （一）会计政策变更的原因 2023 年 10 月 25 日，财政部颁布了《准则解释第 17 号》，其中规定"关于 流动负债与非流动负债的划分"、"关于供应商融资安排的披露"、"关于售后 租回交 ...

一、日常关联交易基本情况 2024 年度日常关联交易预计的核查意见 财通证券股份有限公司（以下简称"财通证券"或"保荐机构"）作为广东 宝莱特医用科技股份有限公司（以下简称"宝莱特"或"公司"）的持续督导保 荐机构，根据《证券发行上市保荐业务管理办法》、《深圳证券交易所上市公司自 律监管指引第2号——创业板上市公司规范运作》、《深圳证券交易所上市公司保 荐工作指引》等有关法律法规和规范性文件的要求，对宝莱特2024年度日常关联 交易预计的事项进行了审慎核查，核查情况如下： 财通证券股份有限公司 关于广东宝莱特医用科技股份有限公司 1、日常关联交易概述 宝莱特结合业务发展需要，对公司及控股子公司与关联方2024年度日常关联 交易情况进行了预计，并于2024年4月24日召开了第八届董事会第十四次会议， 审议通过了《关于2024年度日常关联交易预计的议案》，关联董事燕金元、梁瑾、 廖伟、唐文普在董事会审议该议案时回避了表决。 上述议案预计的关联交易金额在公司董事会决策权限范围内，无需提交公司 股东大会审议。 2、预计日常关联交易类别和金额 单位：万元 | 关联交易 | 关联方 | 关联交易内容 | 关联交易 | 合 ...

广东宝莱特医用科技股份有限公司 会计师事务所选聘制度 广东宝莱特医用科技股份有限公司 会计师事务所选聘制度 第一章 总则 第一条 为进一步规范广东宝莱特医用科技股份有限公司（以下简称"公 司"）选聘会计师事务所的相关行为，提高财务信息质量，根据有关法律法规以 及《广东宝莱特医用科技股份有限公司章程》（以下简称《公司章程》）的有关 规定，结合公司实际情况，制定本制度。 第二条 本制度所称选聘会计师事务所，是指公司根据有关法律法规要求， 聘任会计师事务所对本公司财务会计报告发表审计意见、出具审计报告及内部控 制报告的行为。公司下属全资或控股子公司不再单独选聘会计师事务所。公司聘 任会计师事务所从事其他法定审计业务的，可以参照本制度执行。 （六）定期（至少每年）向董事会提交对受聘会计师事务所的履职情况评估 报告及审计委员会履行监督职责情况报告； -1- 广东宝莱特医用科技股份有限公司 会计师事务所选聘制度 第三条 公司选聘会计师事务所，应当经董事会审计委员会（以下简称"审 计委员会"）审议同意后，提交董事会审议，并由股东大会决定。公司不得在股 东大会决定前委托会计师事务所开展工作。 第四条 审计委员会负责选聘会计师 ...